Longeveron (LGVN) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Chair welcomed shareholders to the third annual meeting, emphasizing virtual participation and support.
Attendees were informed about the meeting's procedures, including question submission and agenda overview.
Executive officers and independent auditors were introduced, with auditors available for questions.
Board and executive committee updates
Four Class III director nominees were presented for election to serve three-year terms expiring in 2027.
No additional nominations were received before the deadline, closing the nominations.
Shareholder proposals
Proposal to elect four directors for three-year terms.
Proposal to amend the 2021 Incentive Award Plan to increase available shares.
Proposal to ratify Marcum LLP as independent auditors for the fiscal year ending December 31, 2024.
Latest events from Longeveron
- Positive clinical progress in stem cell therapies for rare and aging-related diseases.LGVN
Investor presentation18 Mar 2026 - $15M financing extends runway as pivotal HLHS trial nears, despite 50% revenue drop and higher losses.LGVN
Q4 202517 Mar 2026 - Vote sought on reverse stock split to maintain Nasdaq listing and enhance share value.LGVN
Proxy Filing3 Mar 2026 - Revenue and cash up, net loss down, and FDA designations boost growth outlook.LGVN
Q2 20242 Feb 2026 - Revenue up 177%, pivotal trials advanced, and cash runway extends through Q4 2025.LGVN
Q3 202414 Jan 2026 - Lomecel-B advances toward pivotal approval in HLHS and Alzheimer's, targeting billion-dollar markets.LGVN
Emerging Growth Conference7711 Jan 2026 - Lomecel-B shows strong clinical progress in HLHS and Alzheimer's, targeting major unmet needs.LGVN
Biotech Showcase 202510 Jan 2026 - Pivotal trials and 237% revenue growth mark progress, with cash funding into Q4 2025.LGVN
Q4 202426 Dec 2025 - Pivotal HLHS trial nears completion, with BLA filing and accelerated Alzheimer's path planned.LGVN
37th Annual ROTH Conference26 Dec 2025